Abstract There is little doubt that epoetin is a highly Introduction effective treatment for renal anaemia. However, it has been used primarily to treat dialysis patients, in whom There is little doubt that epoetin is a highly effective there is good evidence that it induces significant treatment for the anaemia of renal failure. It has improvements in cardiac function, exercise capacity, transformed the management of this condition, draand quality of life. Unfortunately, none of these three matically reducing the need for blood transfusions, major parameters is completely normalized. There are and replacing previously unsatisfactory treatments three possible reasons for this: (i) the anaemia is not such as the use of androgens. Epoetin is effective in fully corrected, (ii) too much damage has already correcting renal anaemia in 90-95% of patients treated occurred by the time the patient starts dialysis, and [1][2][3], and there are considerable secondary benefits in (iii) other contributory factors may be playing a part. terms of improved cardiac function [4] [5] [6] [7] [8] , exercise Although the effects of completely correcting renal capacity [5, [9] [10] [11] , and quality of life [12] [13] [14] . anaemia have been examined in various studies, the To date, however, epoetin has been used primarily results have not been as positive as expected. It there-to treat dialysis patients, many of whom have been fore seems appropriate to consider a new strategy in exposed to chronic anaemia for a considerable time which epoetin therapy is initiated at an earlier stage in before epoetin therapy is initiated. A large number of the course of the disease, e.g. at a haemoglobin concen-these patients have already developed irreversible, or tration of 11 g/dl or less. It is possible, for example, only partially reversible, changes in cardiac structure, that earlier treatment of anaemia could prevent many such as left ventricular hypertrophy and left ventricular cardiac problems and other morbidities in renal dilatation [15] [16] [17] . It is becoming increasingly apparent patients. In addition, if epoetin therapy is started in that the greater the degree of cardiac damage, the patients who have not been exposed to long-term more difficult it is to reverse the damage, even with chronic anaemia, fewer complications may be encoun-aggressive anaemia treatment. This observation has tered when reversing the anaemia. Higher target ha-stimulated a new approach to the treatment of renal emoglobin concentrations may also be appropriate in anaemia, i.e. starting epoetin at an earlier stage in the these patients. It would certainly be inappropriate, course of the disease. The aim of this article is to however, to extrapolate the data on normalization of discuss not only why this new strategy seems approhaemoglobin in dialysis patients to the pre-dialysis priate, but also why the existing strategy of focusing population. It is therefore necessary to re-examine the on dialysis patients alone is not the solution if signifiissue of optimal target haemoglobin concentration in cant improvements in quality of life, morbidity, and pre-dialysis patients. One of the challenges in the new mortality are to be achieved in the renal failure millennium must be to better understand the con-population. sequences of initiating treatment of anaemia earlier in the course of chronic renal failure.
. The results of most of these studies have been rather disappointing.
The Normal Hematocrit Trial [19] was a randomized, prospective, open-label multicentre study involving 51 centres in the USA. A total of 1233 haemodialysis patients were recruited, all of whom had to have clinical evidence of ischaemic heart disease or congestive heart failure. In the 'intervention' group, which comprised 618 patients, the target haematocrit was 42%. The aim in the 'control' group of 615 patients was to maintain a haematocrit of around 30%. The primary end-point of this study was death or first nonfatal myocardial infarction, and the intended follow- achieved haematocrits in the two groups of patients ( Figure 3) . Nevertheless, the study was aborted prematurely after 29 months due to a borderline damage. There is good evidence that dialysis patients excess mortality in the 'normalized haematocrit' group treated with epoetin show major improvements in ( Figure 4 ). In this group there were 183 deaths and 19 cardiac function [4] [5] [6] [7] [8] , exercise capacity [9] [10] [11] , and first non-fatal myocardial infarctions compared with quality of life [12] [13] [14] . In epoetin-treated patients, the 150 deaths and 14 first non-fatal myocardial infarchigh cardiac output associated with chronic anaemia tions, respectively, in the 'control' group [19] . reverses towards normal [4] , peripheral vascular resistAlthough this study had certain limitations and could ance increases [4] , anginal symptoms lessen [5, 6 ] , and be criticized on a number of points [21] , there is no left ventricular hypertrophy regresses [5, 7, 8] . Patients doubt that the results were disappointing. Certainly, also show an increased capacity for exercise, with objective improvements in maximum oxygen consumption and anaerobic threshold [5, [9] [10] [11] . Quality-oflife parameters, measured using tools such as the Karnofsky Score and the Sickness Impact Profile, also improve significantly [12] [13] [14] in patients treated with epoetin.
Nevertheless, most studies fail to show complete normalization of these physiological defects. Although left ventricular mass decreases, some degree of left ventricular hypertrophy is still evident in many dialysis patients [5, 7, 8] . In most patients, little change is seen in left ventricular dilatation, another abnormality that is known to predispose to cardiac mortality, after anaemia is corrected with epoetin [5, 18] . Quality of but most patients still have subnormal values as compared with normal, healthy, age-and sex-matched controls.
Why are we unable to normalize left ventricular hypertrophy, left ventricular dilatation, exercise capacity, and quality of life in dialysis patients? There are several possible reasons: (i) the anaemia is not fully corrected, (ii) too much damage has already occurred by the time the patient starts dialysis, and (iii) other contributory factors may be playing a part.
Strategy 2
Several clinical studies [11, [18] [19] [20] have investigated whether failure to achieve maximum benefit from epoetin therapy might be due to the fact that anaemia is only partially, not completely, corrected. All of these studies recruited dialysis patients in whom anaemia had already been partially corrected with epoetin; a subgroup of patients was then targeted to achieve attempt should be made to prevent left ventricular dilatation from ever developing, since any intervention, including treatment of anaemia, will be too late to have a positive impact once left ventricular dilatation is present.
In another recent study, McMahon et al. [11] measured exercise capacity following normalization of haemoglobin concentration using a randomized crossover design. All patients in this study were examined at two target haemoglobin concentrations, the first at around 10 g/dl, and the second at around 14 g/dl. Exercise capacity and maximum oxygen consumption were greater at the higher haemoglobin concentration (P<0.01 for all 14 patients) ( Figure 6 ). Even at a normal haemoglobin concentration, however, the exer- Fig. 4 . Normal Hematocrit Trial: probability of death or first non-cise capacity of dialysis patients was still considerably fatal myocardial infarction. (Reproduced with permission from [19] .) lower than that of normal healthy individuals [11] .
There are several possible reasons for the difference: the study provided no evidence to support universal (i) acquired abnormalities in muscle function, (ii) adoption of a 'normalization of haemoglobin' strategy. general systemic effects from sustained uraemia, or A Canadian multicentre trial [18] examined changes (iii) prolonged exposure to anaemia. Again, this study in left ventricular hypertrophy and cavity volume in suggests that a strategy of intervention at an earlier two groups of haemodialysis patients. As with the stage in the course of renal anaemia should be Normal Hematocrit Trial, the target in the 'interven-considered. tion' group was a normal haemoglobin concentration, while the aim in the 'control' group was to maintain a Strategy 3 conventional haemoglobin concentration of around 10-11 g/dl. Although minor improvements in left ven-Another strategy to consider is treating renal anaemia tricular hypertrophy and quality of life were seen in at an earlier stage in its development. In many cases, this study, the main conclusion was that left ventricular this would mean initiation of epoetin therapy before dilatation could not be reversed, even when anaemia the patient needs dialysis ( Figure 7 ). As nephrologists was fully corrected [18] . It was, however, possible to currently strive to treat hypertension early, hyperparaprevent the development of left ventricular dilatation thyroidism early, and malnutrition early, the obvious in patients who had a normal left ventricular cavity question is 'why not anaemia?'. volume at the start of the study; this was in contrast Unfortunately, most of the studies of epoetin therapy to the 'control' patients, many of whom continued to in pre-dialysis patients have involved small numbers show progressive left ventricular dilatation ( Figure 5 ). of patients and short follow-up periods [22] [23] [24] [25] , The obvious conclusion from this study is that an and it is therefore difficult to draw any definitive conclusions from the results. It is known, however, At what haemoglobin concentration should epoetin treatment be initiated? that epoetin is both safe and effective in treating renal What is the optimal target haemoglobin concentration anaemia in pre-dialysis patients. Despite earlier con-in pre-dialysis patients? cerns raised by the results of one animal study [26 ] , How can the benefits of early anaemia treatment in there is now considerable evidence to show that epoetin pre-dialysis patients be maximized? does not worsen the decline in renal function in pre-What impact will early anaemia correction have on dialysis patients [22] [23] [24] [25] .
healthcare services? There are also some preliminary data indicating that It is possible, for example, that epoetin dose requireepoetin improves cardiac function and quality of life ments will be lower in pre-dialysis patients than in in pre-dialysis patients, although evidence from con-patients who are already on renal replacement therapy. trolled studies is still lacking. Several studies in the In the meantime, both the DOQI@ Guidelines [27] and UK, Canada, and Australia, however, are currently the European Best Practice Guidelines [28] suggest examining the effects of earlier anaemia treatment on that the aim should be to maintain the haemoglobin cardiac function, exercise capacity, and quality of life. concentration above 11 g/dl in patients with renal Data from these studies are expected in the near future. failure. It is to be hoped, as data from 'early interven-
The study being conducted in the UK-the UK tion' studies become available, that the scientific rationEarly Intervention Study-involves 25 centres. This ale for this approach will be strengthened. study has recruited patients with a serum creatinine
In the course of the past 10 years, it has become level of between 150 and 500 mmol/l who are not yet increasingly apparent that left ventricular hypertrophy on dialysis. The aim in the 'early intervention' group and left ventricular dilatation, exercise capacity, and is to maintain a haemoglobin concentration of quality of life cannot be normalized if anaemia treat-11±1 g/dl; in the 'triggered intervention' group, the ment is started too late in the course of the disease. haemoglobin concentration is allowed to fall to less Therefore, to limit cardiac damage and maximize the than 9 g/dl before epoetin is started. Major end-points improvements in exercise capacity and quality of life, in this study include left ventricular hypertrophy, the treatment of anaemia must be initiated earlier in exercise capacity, and quality of life.
renal failure patients. The results of studies investigating the effects of epoetin therapy in pre-dialysis patients Strategy 4
are awaited with much hope and expectation. The natural extrapolation from a strategy of treating is a strategy aimed at preventing renal anaemia from ever developing (Figure 8) . Clearly, the 'technology' to achieve this is available, and one of the challenges References in the new millennium must be to investigate in a scientific manner the implications of such an approach. 
